stonks4u
Sign up free
HYPMY logo

HYPMY Hypera S.A.

Other OTC · Drug Manufacturers - Specialty & Generic · Healthcare

$4.19
-0.06 (-1.41%)

Hypera S.A. is a prominent pharmaceutical enterprise primarily operating within Brazil. The company maintains a diverse product portfolio that includes a vast array of prescription medications, marketed under numerous brand names such as Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprog…

Market Cap: $2.95Bwww.hypera.com.br

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
120
Aug 11Aug 11

Quote

Day Range
$4.05 – $4.19
52-Week Range
$3.71 – $5.50
Volume
$200.00
Market Cap
$2.95B
50-Day Avg
$4.10
200-Day Avg
$4.41
Prev Close
$4.25
Open
$4.12

Valuation & Ratios

P/E Ratio
12.00
EPS
$1.89
P/B Ratio
1.15
P/S Ratio
1.86
Debt/Equity
0.75
Current Ratio
1.47
Dividend Yield
+4.4%
Gross Margin
+59.0%

Returns & Efficiency

Return on Equity
+9.5%
Return on Assets
+4.8%
FCF Yield
+12.4%
EV/EBITDA
9.75

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$7.70B$1.20B$1.89
2024$7.44B$1.34B$2.12
2023$7.91B$1.65B$2.58
2022$7.55B$1.70B$2.68
2021$5.94B$1.33B$2.10

Social Signal Score

70
5d
70
1 mentions
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $0.15 per share

1of 1 quarters beat consensus

Typical surprise +7.7% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$0.14 vs $0.13beat

Estimates and results for HYPMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

Project earnings forward and see what return today's price implies.

Seeded from HYPMY's reported EPS growth of -2.6% a year over 4 years.

EPS in 5 years
$1.66
Implied price
$19.88
Return from $4.19
36.5% a year

To earn 15.0% a year on these assumptions you'd need to buy at $9.88 — today's price is already 57.6% below that.

How sensitive is that answer?

Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.

growth \ P/E810121416
-12.6%13.0%18.1%22.5%26.3%29.8%
-7.6%19.4%24.9%29.5%33.6%37.2%
-2.6%25.9%31.6%36.5%40.8%44.6%
2.4%32.4%38.4%43.5%48.0%52.0%
7.4%38.8%45.2%50.5%55.3%59.5%

This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.

Mentions (1)

  • Newsseekingalpha.com·3d ago·Positive

    Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript

    View source ↗